You are here: Industry Insights > Solid Tumors

News List

BMS, Evotec Extend Targeted Protein Degradation Alliance contractpharma
April 27, 2021
Bristol Myers Squibb has exercised its option to extend its partnership with Evotec SE in the field of targeted protein degradation, triggering an undisclosed payment to Evotec.
Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP) americanpharmaceuticalreview
April 07, 2021
Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with ...
I-Mab, MorphoSys Announce First Patient Dosed in Study of TJ210/MOR210 for Advanced Cancer americanpharmaceuticalreview
February 02, 2021
I-Mab and MorphoSys announced the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ210/MOR210 monotherapy in patients with relapsed or refractory ...
Inhibrx Announces Phase 1 Dose Escalation Results of Novel Hexavalent OX40 Agonist americanpharmaceuticalreview
January 13, 2021
Inhibrx has announced results from Part 1 of the Phase 1 dose escalation trial of INBRX-106, a novel hexavalent OX40 agonist, in development for the treatment of solid tumors.
Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for Pedmark to Prevent Ototoxicity Associated With Cisplatin in Pediatric Patients with Localized, No drugs.com
September 23, 2020
Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) on August 10, 2020 from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Pedmark...
SOTIO Announces First Patient Dosed in Part B of Phase 1/1b Study with SO-C101 in Combination with Pembrolizumab in Patients with Solid Tumors b3cnewswire
July 14, 2020
SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that the first patient has been dosed in Part B of the ongoing Phase 1/1b study of IL-15 superagonist, SO-C101, for the treatment of patients with advanced/metastatic soli
Intensity Therapeutics signs clinical collaboration agreement with Bristol Myers Squibb for advanced solid tumors pharmaceutical-business-review
April 17, 2020
Intensity Therapeutics announced it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company.
Yisheng Biopharma receives IND clearance for treatment of advanced solid tumors biospectrumasia
June 28, 2019
YS-ON-001 has received Orphan Drug Designation from the U.S FDA for development of the treatment for both hepatocellular cancer and pancreatic cancer, and is approved for use in Cambodia as YivykaTM.
Targovax Announces Completed Enrollment of ONCOS-102 Trial in Mesothelioma prnewswire
May 08, 2019
Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that it has completed patient enrollment in the phase...
Bayer to Obtain Rights to Vitrakvi and BAY 2731954 americanpharmaceuticalreview
February 18, 2019
Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization...

Previous page 1 2 3 Next page